Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24


A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.

Thomson CA, Chow HHS, Wertheim BC, Roe DJ, Stopeck A, Maskarinec G, Altbach M, Chalasani P, Huang C, Strom MB, Galons JP, Thompson PA.

Breast Cancer Res Treat. 2017 Aug;165(1):97-107. doi: 10.1007/s10549-017-4292-7. Epub 2017 May 30.


Harnessing the Power of Cruciferous Vegetables: Developing a Biomarker for Brassica Vegetable Consumption Using Urinary 3,3'-Diindolylmethane.

Fujioka N, Ransom BW, Carmella SG, Upadhyaya P, Lindgren BR, Roper-Batker A, Hatsukami DK, Fritz VA, Rohwer C, Hecht SS.

Cancer Prev Res (Phila). 2016 Oct;9(10):788-793. Epub 2016 Aug 18.


Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies.

Thomson CA, Ho E, Strom MB.

Nutr Rev. 2016 Jul;74(7):432-43. doi: 10.1093/nutrit/nuw010. Epub 2016 May 31. Review.


Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients.

Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, Menon M, Peabody JO, Smith DW, Sarkar FH, Heath EI.

Am J Transl Res. 2016 Jan 15;8(1):166-76. eCollection 2016.


Intestinal inflammation and the diet: Is food friend or foe?

Megna BW, Carney PR, Kennedy GD.

World J Gastrointest Surg. 2016 Feb 27;8(2):115-23. doi: 10.4240/wjgs.v8.i2.115. Review.


Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane's efficacy and safety in the treatment of CIN: implications for cervical cancer prevention.

Ashrafian L, Sukhikh G, Kiselev V, Paltsev M, Drukh V, Kuznetsov I, Muyzhnek E, Apolikhina I, Andrianova E.

EPMA J. 2015 Dec 21;6:25. doi: 10.1186/s13167-015-0048-9. eCollection 2015.


An open label pilot study to evaluate the efficacy of Spanish black radish on the induction of phase I and phase II enzymes in healthy male subjects.

Evans M, Paterson E, Barnes DM.

BMC Complement Altern Med. 2014 Dec 9;14:475. doi: 10.1186/1472-6882-14-475.


Multiple therapeutic and preventive effects of 3,3'-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia.

Zhang WW, Feng Z, Narod SA.

J Biomed Res. 2014 Sep;28(5):339-48. doi: 10.7555/JBR.28.20140008. Epub 2014 Apr 20.


A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones.

Chow HH, Garland LL, Heckman-Stoddard BM, Hsu CH, Butler VD, Cordova CA, Chew WM, Cornelison TL.

J Transl Med. 2014 Aug 14;12:223. doi: 10.1186/s12967-014-0223-0.


BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.

Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P, Narod SA.

Br J Cancer. 2014 Sep 23;111(7):1269-74. doi: 10.1038/bjc.2014.391. Epub 2014 Jul 15.


Natural compounds as anticancer agents: Experimental evidence.

Wang J, Jiang YF.

World J Exp Med. 2012 Jun 20;2(3):45-57. doi: 10.5493/wjem.v2.i3.45. eCollection 2012 Jun 20. Review.


Comparative preclinical pharmacokinetics study of 3,3'-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon?

Paltsev M, Kiselev V, Muyzhnek E, Drukh V, Kuznetsov I, Pchelintseva O.

EPMA J. 2013 Dec 10;4(1):25. doi: 10.1186/1878-5085-4-25.


DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism.

Fan S, Meng Q, Xu J, Jiao Y, Zhao L, Zhang X, Sarkar FH, Brown ML, Dritschilo A, Rosen EM.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18650-5. doi: 10.1073/pnas.1308206110. Epub 2013 Oct 14.


Multi-nutrient supplement improves hormone ratio associated with cancer risk.

Bazzan AJ, Zabrecky GP, Newberg AB.

J Transl Med. 2013 Oct 8;11:252. doi: 10.1186/1479-5876-11-252.


Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention.

W Watson G, M Beaver L, E Williams D, H Dashwood R, Ho E.

AAPS J. 2013 Oct;15(4):951-61. doi: 10.1208/s12248-013-9504-4. Epub 2013 Jun 26. Review.


Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic.

Banerjee S, Kong D, Wang Z, Bao B, Hillman GG, Sarkar FH.

Mutat Res. 2011 Jul-Oct;728(1-2):47-66. doi: 10.1016/j.mrrev.2011.06.001. Epub 2011 Jun 15. Review.


Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells.

Marconett CN, Sundar SN, Tseng M, Tin AS, Tran KQ, Mahuron KM, Bjeldanes LF, Firestone GL.

Carcinogenesis. 2011 Sep;32(9):1315-23. doi: 10.1093/carcin/bgr116. Epub 2011 Jun 21.


Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer.

Rajoria S, Suriano R, George A, Shanmugam A, Schantz SP, Geliebter J, Tiwari RK.

PLoS One. 2011 Jan 18;6(1):e15879. doi: 10.1371/journal.pone.0015879.


3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study.

Rajoria S, Suriano R, Parmar PS, Wilson YL, Megwalu U, Moscatello A, Bradlow HL, Sepkovic DW, Geliebter J, Schantz SP, Tiwari RK.

Thyroid. 2011 Mar;21(3):299-304. doi: 10.1089/thy.2010.0245. Epub 2011 Jan 22.


Selective activation of estrogen receptor-beta target genes by 3,3'-diindolylmethane.

Vivar OI, Saunier EF, Leitman DC, Firestone GL, Bjeldanes LF.

Endocrinology. 2010 Apr;151(4):1662-7. doi: 10.1210/en.2009-1028. Epub 2010 Feb 16.

Supplemental Content

Support Center